Agrimonia coreana Extract Exerts Its Therapeutic Effect through CRAC Channel Inhibition for Atopic Dermatitis Treatmentopen access
- Authors
- Kim, Jintae; Lee, Ji Min; Park, Su Jin; Nam, Yu Ran; Choi, Seong Woo; Nam, Joo Hyun; Kim, Hyun Jong; Kim, Woo Kyung
- Issue Date
- Aug-2024
- Publisher
- Multidisciplinary Digital Publishing Institute (MDPI)
- Keywords
- Agrimonia coreana; Atopic dermatitis; CRAC channel; T lymphocyte
- Citation
- International Journal of Molecular Sciences, v.25, no.16, pp 1 - 13
- Pages
- 13
- Indexed
- SCIE
SCOPUS
- Journal Title
- International Journal of Molecular Sciences
- Volume
- 25
- Number
- 16
- Start Page
- 1
- End Page
- 13
- URI
- https://scholarworks.dongguk.edu/handle/sw.dongguk/23029
- DOI
- 10.3390/ijms25168894
- ISSN
- 1661-6596
1422-0067
- Abstract
- Atopic dermatitis (AD) is a common allergic inflammatory skin condition marked by severe itching, skin lichenification, and chronic inflammation. AD results from a complex immune response, primarily driven by T lymphocytes and environmental triggers, leading to a disrupted epidermal barrier function. Traditional treatments, such as topical corticosteroids, have limitations due to long-term side effects, highlighting the need for safer alternatives. Here, we aimed to show that Agrimonia coreana extract (ACext) can be used in treating AD-related dermatologic symptoms. ACext could inhibit CRAC (Calcium Release-Activated Calcium) channel activity, reducing Orai1/CRAC currents and decreasing intracellular calcium signaling. This inhibition was further confirmed by the reduced IL-2 levels and T cell proliferation upon ACext treatment. In a mouse model of AD, ACext significantly ameliorates symptoms, improves histological parameters, and enhances skin barrier function, demonstrating its potential for treating AD. © 2024 by the authors.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Medicine > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.